BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29973561)

  • 1. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.
    Schrank Z; Chhabra G; Lin L; Iderzorig T; Osude C; Khan N; Kuckovic A; Singh S; Miller RJ; Puri N
    Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29973561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer.
    Chhabra G; Eggert A; Puri N
    Arch Cancer Res; 2015; 3(3):. PubMed ID: 27280107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.
    Rohilla S; Singh M; Alzarea SI; Almalki WH; Al-Abbasi FA; Kazmi I; Afzal O; Altamimi ASA; Singh SK; Chellappan DK; Dua K; Gupta G
    J Environ Pathol Toxicol Oncol; 2023; 42(1):27-50. PubMed ID: 36734951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
    Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
    Johnson M; Garassino MC; Mok T; Mitsudomi T
    Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
    Asao T; Takahashi F; Takahashi K
    Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
    Gao J; Li HR; Jin C; Jiang JH; Ding JY
    Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application.
    Maione P; Sacco PC; Sgambato A; Casaluce F; Rossi A; Gridelli C
    Ther Adv Med Oncol; 2015 Sep; 7(5):263-73. PubMed ID: 26327924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in
    Shaurova T; Zhang L; Goodrich DW; Hershberger PA
    Front Genet; 2020; 11():281. PubMed ID: 32292420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
    Koga T; Suda K; Mitsudomi T
    Cancer Sci; 2022 Mar; 113(3):815-827. PubMed ID: 34997674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
    Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
    Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
    Santarpia M; Gil N; Rosell R
    Expert Rev Clin Pharmacol; 2015; 8(4):461-77. PubMed ID: 26068305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.
    Zhou C; Yao LD
    J Thorac Oncol; 2016 Feb; 11(2):174-86. PubMed ID: 26845114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.